Licensed providers. In-home visits in Las Vegas, North Las Vegas and Brooklyn, NY.
(718) 218-4791info@briyahealth.comA plain-language look at the growth hormone-releasing hormone analog — what it does at the pituitary, why the brand-name product left the US market in 2008, what the adult research does and does not establish, and how it reaches patients today.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
Sermorelin acetate is a synthetic fragment of growth hormone-releasing hormone, the 44-amino-acid messenger the hypothalamus uses to tell the pituitary gland to release growth hormone. Researchers found that the first 29 amino acids carry essentially all of the biological activity, so that shortened version, GHRH(1-29), became the drug. It belongs to a class called growth hormone secretagogues: substances that prompt a gland to secrete a hormone rather than supplying that hormone directly.
Not currently. The brand-name product, Geref, was approved twice in the United States: in December 1990 as a diagnostic agent for testing the pituitary's ability to release growth hormone, and in September 1997 for treating idiopathic growth hormone deficiency in children with growth failure. The manufacturer, EMD Serono, discontinued both in 2008, and in 2013 the FDA formally determined they had not been withdrawn for reasons of safety or effectiveness. No FDA-approved sermorelin product has been on the US market since, so every sermorelin prescription filled today is a compounded preparation.
Through compounding pharmacies. Under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy may compound a preparation from a bulk substance if that substance meets certain conditions, one of which is being a component of an FDA-approved drug. Because sermorelin was the active ingredient in an approved product, it satisfies that pathway, which is why it remains available with a patient-specific prescription while many other peptides do not. Compounded preparations are not FDA-approved: they are not reviewed for safety, effectiveness or manufacturing quality the way an approved drug is.
Recombinant human growth hormone is the hormone itself, delivered directly into the bloodstream. Sermorelin acts a step upstream, asking the pituitary to release more of its own. The practical difference is the shape of the resulting hormone curve: injected growth hormone produces steady, non-pulsatile levels and suppresses the body's own GHRH output through feedback, while a secretagogue works within the existing pulsatile rhythm and leaves the somatostatin brake intact. The important caveat is that this is a physiological argument, not an outcomes one. Growth hormone has decades of controlled data behind it; sermorelin does not.
Considerably less than the marketing around it suggests. The adult literature consists largely of small studies, many from the 1990s, measuring hormone levels and short-term body composition rather than long-term clinical outcomes. There are no large randomized trials establishing that sermorelin improves body composition, bone density, cardiovascular risk or quality of life in adults over years of use, and no long-term safety dataset. Anyone weighing it should understand they are working from a thin evidence base, which is a different situation from the GLP-1 medications covered elsewhere in this Learning Center.
It is given as a small subcutaneous injection, typically at night on an empty stomach. The timing is deliberate: the body's largest natural growth hormone pulse occurs during early deep sleep, so dosing before bed is intended to work with that rhythm rather than against it. Because compounded preparations vary in concentration and protocol, the specific dose and schedule come from the prescribing provider rather than from a standard label.
Elevated blood sugar and insulin blunt growth hormone release, so a meal shortly before dosing works against the intended effect. This is the same physiological reason growth hormone pulses are largest during fasting and sleep. Providers commonly advise leaving a gap after eating, particularly after carbohydrate-heavy meals.
The most frequently reported effects are local: redness, swelling or discomfort at the injection site, which the original Geref labeling described in about one patient in six. Flushing, headache, dizziness, nausea and a transient warm sensation have also been described. The pediatric labeling also reported hypothyroidism developing during treatment in 6.5% of children and antibodies to the drug in a large proportion of patients. Because sermorelin raises growth hormone and downstream IGF-1, the theoretical concerns associated with growth hormone excess apply as well, including fluid retention, joint aches, carpal tunnel symptoms and effects on blood sugar. A thin long-term dataset in adults means uncommon effects may simply not have been captured.
Known hypersensitivity to sermorelin acetate is a clear contraindication, as are pregnancy and breastfeeding, where safety data are inadequate. Active malignancy is a standard exclusion for growth hormone secretagogues, since the GH and IGF-1 axis influences cell growth. Untreated hypothyroidism is not an absolute barrier but should be corrected first, because it blunts the pituitary's response to GHRH and makes the medication less likely to do anything. A full medical history belongs in the conversation before starting.
Glucocorticoids suppress growth hormone secretion and can blunt the response substantially. Thyroid status matters for the same reason. Because sermorelin shifts GH and IGF-1 levels, it can also interact with other hormone therapies, so anyone on testosterone, estrogen or thyroid replacement should have those reviewed together rather than in isolation. It does not carry the thyroid C-cell tumor boxed warning associated with GLP-1 receptor agonists; the mechanisms and risk profiles are unrelated.
IGF-1 is the standard marker. Growth hormone itself is released in pulses and a single random measurement tells you very little, whereas IGF-1 is produced largely by the liver in response to growth hormone and stays relatively stable through the day, making it a usable proxy. A baseline before starting and follow-up measurements afterward are the usual approach. Thyroid function and fasting glucose are commonly checked alongside it, since both influence and are influenced by this axis.
Reported timelines vary widely and come mostly from clinical observation rather than controlled trials. Sleep quality is the change people most often describe first, within the early weeks. Body composition changes, where they occur, are described over months rather than weeks. Given how thin the trial evidence is, any specific timeline presented as established fact should be treated with caution.
It is not a weight-loss medication and has no approval or trial basis for that use. Growth hormone influences how the body partitions fat and lean tissue, which is the mechanism behind claims about body composition, but that is a different thing from producing weight loss. The medications with demonstrated weight-loss effects in randomized trials are the GLP-1 receptor agonists, not growth hormone secretagogues.
Both are GHRH analogs, but their regulatory positions differ sharply. Tesamorelin is a stabilized analog of the full 44-amino-acid GHRH that received FDA approval in 2010 for reducing excess abdominal fat in people with HIV-associated lipodystrophy, supported by randomized trials, and it remains on the market. Sermorelin is the shorter GHRH(1-29) fragment, approved in 1990 as a diagnostic agent and in 1997 for children with growth hormone deficiency, and discontinued in 2008. Similar class, very different evidence and approval status.
They are often discussed together, but their legal standing differs. Ipamorelin works through the ghrelin receptor rather than the GHRH receptor, and CJC-1295 is a long-acting GHRH analog. Both were placed in Category 2 of the FDA's interim 503A bulk substances list, the category for substances flagged with potential safety risks, and their nominations were later withdrawn, which means compounding pharmacies cannot lawfully prepare them. Sermorelin's status is different because it was a component of an approved drug. Any source offering those peptides for human use is worth scrutinizing carefully.
It is a recognized endocrine condition, usually stemming from pituitary disease, surgery, radiation or trauma, characterized by increased abdominal fat, reduced muscle mass, low bone density and effects on quality of life. Because those signs are nonspecific, diagnosis requires formal stimulation testing rather than symptoms alone. It is a distinct clinical entity from the gradual decline in growth hormone that accompanies normal aging, and the two should not be conflated.
Because growth hormone is released in pulses, a single blood level cannot establish deficiency. Diagnosis relies on stimulation testing, historically the insulin tolerance test, with GHRH plus arginine as a common alternative. When the GHRH-based diagnostic product was withdrawn from the US market, that alternative became harder to perform, which contributed to the development of macimorelin, an orally administered ghrelin mimetic approved for diagnosing adult growth hormone deficiency.
Not by itself. IGF-1 falls naturally with age, and reference ranges are age-adjusted for that reason, so a result below a young adult's range may be entirely normal for someone older. IGF-1 is also lowered by poor nutrition, liver disease, untreated hypothyroidism and poorly controlled diabetes. A single number is a starting point for a conversation, not a diagnosis, and confirming true deficiency requires stimulation testing.
Growth hormone output declines with age, and that observation is the basis for the anti-aging framing. What has not been established is that raising it back up in otherwise healthy adults extends healthy lifespan or prevents age-related disease. No randomized trial has shown that for sermorelin. The physiological rationale is coherent; the outcome evidence that would turn it into a proven anti-aging intervention does not exist yet.
It is not a federally controlled substance, but it is prohibited in competitive sport. The World Anti-Doping Agency bans growth hormone-releasing factors and their analogs, including GHRH analogs, at all times, in and out of competition. Any athlete subject to drug testing should treat a prescription as disqualifying unless a therapeutic use exemption has been granted.
Generally not. Insurers typically do not cover compounded preparations that lack an FDA-approved equivalent, and they do not cover treatments used outside an approved indication. Patients should expect this to be an out-of-pocket expense and should ask for the full cost, including follow-up laboratory testing, before committing.
Whether the pharmacy is licensed by its state board of pharmacy, whether its sermorelin bulk ingredient comes from an FDA-registered supplier with a certificate of analysis, and whether sterile preparations are made and tested under United States Pharmacopeia chapter 797 standards, including how beyond-use dates are set. A legitimate pharmacy will answer these questions readily. Material labeled research use only is not authorized for human use, however it is marketed.
Products sold online under a research use only label sit outside the prescription system entirely: nobody has verified identity, purity, sterility or concentration, and injecting an unverified sterile preparation carries infection and contamination risk on top of dosing uncertainty. Purchasing them for human use also bypasses federal law. The presence of a certificate of analysis on a website is not the same as an independently verified one.
Peptides are fragile. Compounded sermorelin is typically supplied either as a lyophilized powder for reconstitution or as a pre-mixed solution, and both are generally refrigerated and protected from light, never frozen once reconstituted. Beyond-use dating for compounded sterile preparations is set by the pharmacy and is usually much shorter than the expiration date on a manufactured drug, so the label that comes with your vial is the authority.
This is the central theoretical argument for secretagogues over growth hormone itself. Injected growth hormone suppresses the body's own GHRH through negative feedback, while a GHRH analog works through the existing control system, leaving somatostatin, the body's natural brake, able to limit release. The reasoning is sound physiology, but it has not been tested against hard outcomes in long-term adult trials, so it should be understood as a mechanistic argument rather than a proven advantage.
Sermorelin is cleared from the bloodstream very quickly, with a half-life of about 11 to 12 minutes according to the original labeling, and its effect on growth hormone release depends on continued dosing. Hormone levels would be expected to return to their pre-treatment baseline once it is stopped, along with any effects that depended on them. There is no established withdrawal syndrome, and no controlled data on what happens to body composition over time after discontinuation.
These hormones influence one another, so the combination is a matter for a prescriber who can see the whole picture rather than something to assemble piecemeal. Thyroid status in particular affects how the pituitary responds, and untreated hypothyroidism should be corrected first. Stacking multiple hormone therapies without coordinated monitoring makes it difficult to tell which one is producing an effect, or a side effect.
Growth hormone opposes some of insulin's actions, and reduced insulin sensitivity is a recognized effect of growth hormone therapy. Whether the smaller, pulsatile rises produced by a secretagogue carry the same risk has not been established in long-term studies. Anyone with diabetes, prediabetes or insulin resistance has good reason to have glucose and HbA1c monitored during treatment rather than assumed to be unaffected.
There is no evidence that sermorelin causes cancer, but there is also no long-term study large enough to rule out a small effect. The concern is theoretical and comes from the biology: IGF-1 promotes cell growth and inhibits programmed cell death, which is why active malignancy is a standard exclusion for growth hormone secretagogues. Anyone with a personal or strong family history of cancer should raise it explicitly before starting.
Much of the marketing around sermorelin borrows from the growth hormone literature. Studies of recombinant growth hormone in adults with diagnosed deficiency do show improvements in body composition, bone density and quality of life, and those findings are frequently presented as though they transfer directly to a secretagogue in adults without diagnosed deficiency. They are two different interventions in two different populations. Reading any claim carefully enough to ask which drug was studied, and in whom, resolves most of the confusion.
Useful questions include: what specifically are we trying to change, and how will we measure whether it worked; what testing supports the reason for prescribing it; what would make us stop; what is the total cost including laboratory follow-up; and what is the evidence behind the expected benefit. A prescriber who can distinguish between what is established and what is extrapolated is giving you the information you need to decide.
Twice, under the brand name Geref. The FDA approved it in December 1990 as a diagnostic agent for testing the pituitary's growth hormone response, and in September 1997 for treating idiopathic growth hormone deficiency in children with growth failure. It was never approved for use in adults outside diagnostic testing.
The manufacturer, EMD Serono, discontinued both Geref products in 2008, and the FDA withdrew the approvals in 2009. In 2013 the FDA published a formal determination in the Federal Register that Geref had not been withdrawn for reasons of safety or effectiveness, which means a generic version could in principle be approved.
No. The April 2026 removal of 12 peptides from Category 2 and the July 2026 advisory committee votes concerned substances such as BPC-157, TB-500 and MOTS-c. Sermorelin was not on that list, because pharmacies compound it through a separate route: it was the active ingredient in an FDA-approved drug.
There is no published controlled evidence that they do. Even subcutaneous injection delivered only about 6% of the dose into the bloodstream according to the original labeling, and peptides taken by mouth are largely broken down in the digestive tract. Intranasal GHRH has been studied in research settings but required much larger doses and gave less consistent results.
Only minutes. The original labeling reported a half-life of about 11 to 12 minutes, with peak levels 5 to 20 minutes after a subcutaneous injection. Each dose produces a single growth hormone pulse that peaks within about an hour, which is why its effects depend on continued daily use.
GHRH is linked to deep sleep, and in studies of young adults GHRH given at night increased slow-wave sleep. Results in older adults have been mixed and weaker. Reports of better sleep on sermorelin come mainly from patient experience rather than controlled trials, so the size and consistency of any effect are unknown.
It has not been shown to. The best evidence comes from a 2012 trial of tesamorelin, a related GHRH analog, in 152 older adults, which found a modest improvement in executive function over 20 weeks. That result has not led to an approved use, and no comparable trial has been done with sermorelin.
Usually not well. Sermorelin works by stimulating the pituitary's growth hormone-producing cells, so if those cells have been damaged by a tumor, surgery or radiation, there may be little left to respond. Adults with deficiency from pituitary disease are generally treated with growth hormone replacement under an endocrinologist's care.
Exercise, particularly higher-intensity aerobic and resistance training, produces substantial growth hormone pulses. Adequate deep sleep, avoiding alcohol and large meals late at night, treating sleep apnea and reducing abdominal fat all support natural secretion. These measures also have well-documented benefits for overall health.
Growth hormone release is controlled by a chain of signals. The hypothalamus produces growth hormone-releasing hormone, a 44-amino-acid messenger that travels a short distance to the anterior pituitary and instructs it to release growth hormone. Growth hormone then acts on tissues throughout the body, much of it indirectly, by prompting the liver to produce insulin-like growth factor 1. Researchers established decades ago that the first 29 amino acids of GHRH carry essentially all of its biological activity, which made the truncated version a practical drug candidate. That fragment, GHRH(1-29), is sermorelin acetate.
This places sermorelin in a category called growth hormone secretagogues: substances that cause a gland to secrete a hormone rather than supplying the hormone itself. The distinction is not cosmetic. Recombinant human growth hormone, the medication given to children with growth failure and to adults with proven deficiency, is the hormone. Sermorelin is an instruction to produce more of it. Everything the marketing claims as an advantage flows from that difference, and so does the main limitation: if the pituitary cannot respond, an instruction achieves nothing.
Sermorelin is sold and discussed under several names, and the overlap causes confusion. Sermorelin acetate is the formal name of the drug. GRF 1-29, GHRH(1-29) and growth hormone-releasing factor 1-29 all refer to the same 29-amino-acid sequence. Geref was the brand name of the FDA-approved products discontinued in 2008.
A different compound, often called Modified GRF 1-29 or Mod GRF 1-29, is sometimes marketed as if it were an improved version of sermorelin. It is the same 29-amino-acid backbone with four amino acids substituted to resist enzyme breakdown, which extends its activity from minutes to somewhat longer. It is closely related to CJC-1295; the version without the albumin-binding group is sometimes sold as CJC-1295 without DAC. It has never been approved, is not the active ingredient of any approved drug, and does not share sermorelin's compounding pathway.
The naming matters because the legal and evidentiary positions differ. Sermorelin can be compounded by licensed pharmacies because it was the active ingredient in Geref. Modified GRF 1-29 and CJC-1295 are generally sold as research chemicals, and CJC-1295 was placed in Category 2 of the FDA's interim compounding list before its nomination was withdrawn. A product labeled with one name may, in practice, contain something different, which only laboratory testing can reveal.
When reviewing a prescription or product, it is worth confirming that the ingredient is sermorelin acetate, that it comes from a licensed pharmacy with a patient-specific label, and that the concentration is stated clearly. Products that use the names interchangeably, or that combine sermorelin with other secretagogues in one vial, are signs that the supplier may be operating outside the regulated compounding system.
Growth hormone secretion differs between men and women. Women of reproductive age tend to secrete more growth hormone overall than men of the same age, with a less sharply pulsatile pattern, largely because estrogen increases secretion. Testosterone also stimulates the axis in men, partly after being converted to estrogen in the body. These differences mean that the same dose of a secretagogue does not necessarily produce the same response in everyone.
The route of estrogen matters as well. Estrogen taken by mouth passes through the liver first, where it reduces the liver's production of IGF-1 in response to growth hormone. Women taking oral estrogen, whether as contraception or menopausal hormone therapy, can therefore have lower IGF-1 for a given amount of growth hormone, and guidelines on growth hormone replacement note that they often need higher doses. Estrogen delivered through the skin has much less of this effect.
In the small studies of GHRH in older adults from the 1990s, effects on body composition were generally smaller or absent in women compared with men, although the studies were too small to establish a firm difference. Menopause itself changes the growth hormone axis, and interpreting IGF-1 results in women requires knowing whether and how they take estrogen.
For anyone considering sermorelin, these points have practical consequences. IGF-1 targets and reference ranges are sex-specific, and a result should be interpreted alongside any hormone therapy being used. Changes to estrogen or testosterone treatment during sermorelin use can shift IGF-1 independently of the sermorelin itself, which is one reason coordinated monitoring of hormone therapies is recommended rather than adjusting each in isolation.
The idea that the brain controls growth through hormones released into the blood supply of the pituitary took shape in the 1950s and 1960s, and isolating those hormones became one of the major scientific races of the era. In 1973 a team led by Roger Guillemin at the Salk Institute isolated somatostatin, the hypothalamic hormone that inhibits growth hormone release. Guillemin and Andrew Schally shared the 1977 Nobel Prize in Physiology or Medicine for their work on hypothalamic hormones, but the stimulating hormone, GHRH, had still not been found.
The breakthrough came from an unusual source. A small number of people with acromegaly, the condition caused by excess growth hormone, turned out to have tumors outside the pituitary, usually in the pancreas, that secreted a substance driving their pituitaries to overproduce growth hormone. In 1982, research groups led by Guillemin and by Wylie Vale and Jean Rivier independently isolated and sequenced GHRH from such pancreatic tumors. The human hypothalamic hormone was confirmed to be a 44-amino-acid peptide.
Researchers quickly established that shorter fragments of GHRH retained its activity, and that the first 29 amino acids were the shortest sequence with essentially full potency. That fragment was simpler and cheaper to synthesize, and it became sermorelin. Within a few years it was being tested as a diagnostic agent to distinguish hypothalamic from pituitary causes of growth hormone deficiency, and as a potential treatment for children whose pituitaries were intact but under-stimulated.
The discovery story matters for understanding sermorelin's limits. GHRH acts only on the pituitary. If the pituitary's growth hormone-producing cells have been destroyed by a tumor, surgery or radiation, stimulating them achieves little, which is why growth hormone replacement, not a GHRH analog, remains the treatment for most forms of adult deficiency. The acromegaly tumors that revealed GHRH also illustrate its power: sustained, unregulated GHRH stimulation can enlarge the pituitary and drive growth hormone excess.
Sermorelin acts on the GHRH receptor, a protein on the surface of somatotrophs, the growth hormone-producing cells of the anterior pituitary. The receptor belongs to the large family of G protein-coupled receptors, the same broad class targeted by GLP-1 drugs, and when activated it raises levels of a messenger molecule called cyclic AMP inside the cell.
That signal has several effects. In the short term it triggers the release of growth hormone already stored in the cell, which is why a dose produces a rise in blood growth hormone within minutes. Over longer periods, GHRH signaling increases production of new growth hormone by switching on the growth hormone gene, and it promotes the growth and multiplication of somatotrophs themselves. That last effect is why sustained excess GHRH, as in the rare tumors that secrete it, can enlarge the pituitary.
Somatostatin works against GHRH at the same cells, suppressing release even when GHRH is present. The balance between the two, together with ghrelin acting at a separate receptor, shapes the pulsatile pattern of growth hormone secretion. Because sermorelin works through this system rather than around it, the body's own inhibitory signals still apply, and IGF-1 continues to exert negative feedback. That is the basis for the claim that GHRH analogs have a built-in ceiling, although the ceiling is not absolute and has not been quantified for long-term use.
GHRH receptors are not confined to the pituitary. They have been found in other tissues, including some tumors, which has led cancer researchers to develop GHRH antagonists, drugs that block the receptor, as experimental cancer treatments. This line of research does not show that sermorelin causes cancer, but it is one reason the growth hormone axis is approached cautiously in people with a history of malignancy.
Sermorelin was developed during research into peptide-based regulation of the hypothalamic-pituitary axis and entered clinical practice first as a diagnostic tool, used to assess whether a pituitary could mount a growth hormone response. The FDA approved it under the brand name Geref in December 1990 for that diagnostic use, and in September 1997 approved a second Geref product for treating idiopathic growth hormone deficiency in children with growth failure. In children it was recognized as less effective than growth hormone itself and unsuitable for deficiencies originating in the pituitary rather than the hypothalamus.
Its clinical use never became widespread. Alternative diagnostic strategies and better hormone assays reduced the need for it, and the manufacturer, EMD Serono, discontinued both Geref products in 2008; the FDA withdrew the approvals in 2009 and determined in 2013 that they had not been withdrawn for reasons of safety or effectiveness. The discontinuation had a practical consequence beyond sermorelin itself: the GHRH plus arginine stimulation test, endorsed by consensus guidelines as the main alternative to the insulin tolerance test, became difficult to perform in the United States. That gap contributed to the development of macimorelin, an oral ghrelin mimetic approved in 2017 for diagnosing adult growth hormone deficiency.
A single timeline helps make sense of claims about sermorelin's status. In 1973, somatostatin was isolated. In 1982, GHRH was isolated and sequenced, and the 29-amino-acid fragment that became sermorelin was identified as fully active soon after. In December 1990, the FDA approved Geref for diagnostic use in evaluating the pituitary's growth hormone response. In September 1997, it approved a second Geref product for treating idiopathic growth hormone deficiency in children with growth failure.
In 2008 the manufacturer, EMD Serono, discontinued both products. The FDA withdrew the approvals in June 2009 at the company's request, and in March 2013 it published a formal determination in the Federal Register that Geref had not been withdrawn for reasons of safety or effectiveness. That determination means a generic version could in principle be approved through the abbreviated pathway, although none has reached the market.
Other events shaped the surrounding landscape. Tesamorelin, a stabilized full-length GHRH analog, was approved in 2010 for HIV-associated lipodystrophy. Macimorelin, an oral ghrelin mimetic, was approved in 2017 as a diagnostic test for adult growth hormone deficiency, partly filling the gap left by the loss of GHRH-based testing. In 2023 the FDA placed a number of other peptides, including the secretagogues ipamorelin and CJC-1295 and the repair peptide BPC-157, in Category 2 of its interim compounding list.
In 2026 the FDA announced it would remove 12 peptides from Category 2 and refer them to its compounding advisory committee, which voted in July 2026 to recommend six of them. Sermorelin was not part of that process, because its compounding status rests on a different legal basis: it was the active ingredient in an approved drug. Keeping these dates straight is useful because marketing often blurs them, describing sermorelin as FDA-approved without mentioning that no approved product has existed since 2008.
Sermorelin's treatment approval was for children, and the pediatric program is the most substantial clinical evidence it has. The target population was children with idiopathic growth hormone deficiency, meaning deficiency without an identified structural cause, many of whom were thought to have a hypothalamic problem with an intact pituitary. In that situation, supplying the missing stimulus made biological sense.
The Geref International Study Group reported in 1996 that once-daily subcutaneous injections at bedtime accelerated growth in growth hormone-deficient children during the first year of treatment. Across the clinical program, about 350 patients were exposed to the drug. Response was variable, however, and growth hormone itself generally produced more reliable growth, which is part of why sermorelin never displaced it as the standard pediatric treatment.
The pediatric labeling documented several safety findings. Local injection reactions were the most common effect, occurring in about one patient in six. Hypothyroidism developed during treatment in 6.5% of children, so thyroid function was monitored, since untreated hypothyroidism also blunts the response. A large proportion of patients developed antibodies to the drug at least once during treatment, although their clinical significance was not clearly established.
None of this establishes benefit in adults. The pediatric studies measured growth in children with a diagnosed deficiency, an outcome that has no equivalent in adults whose growth plates have closed. Today, children with poor growth are evaluated by pediatric endocrinologists and, where treatment is indicated, receive approved growth hormone products. Sermorelin's pediatric history is relevant mainly as evidence that the molecule is biologically active and reasonably tolerated over months, not as evidence of what it does for adults.
With no approved product on the market, every sermorelin prescription filled in the United States today is a compounded preparation. Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound from a bulk substance when that substance meets one of a few specific conditions, including being a component of an FDA-approved drug. Sermorelin satisfies that condition because it was the active ingredient in an approved product, which is why it remains available with a patient-specific prescription.
That position is not shared by every peptide marketed alongside it. The FDA maintains an interim list of nominated bulk substances divided into categories, and substances placed in Category 2 have been flagged for potential significant safety risks, meaning the agency would consider enforcement action against a pharmacy compounding them. Several growth hormone secretagogues discussed in the same breath as sermorelin, including ipamorelin and CJC-1295, were placed in that category and later had their nominations withdrawn. A compounded preparation is still not an FDA-approved drug: it has not been evaluated for safety, effectiveness or manufacturing quality, and its consistency depends on the pharmacy that made it.
The peptide compounding landscape changed substantially in 2026, and it is easy to assume sermorelin was part of those changes. It was not. On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2, the list of substances it had flagged for significant safety concerns, and send them to its Pharmacy Compounding Advisory Committee. The committee met on July 23 and 24, 2026, and recommended six of the seven peptides it reviewed, including BPC-157 and TB-500, for addition to the 503A bulks list.
Sermorelin sits outside that process because it does not need the bulks list. A 503A pharmacy may compound from a bulk substance that is a component of an FDA-approved drug, and sermorelin was the active ingredient of Geref. That route has allowed licensed pharmacies to compound it throughout the period in which many other peptides were restricted.
Two caveats apply. First, legal compounding is not the same as FDA approval. A compounded preparation has not been reviewed for safety, effectiveness or manufacturing quality, and it must be prepared for an individual patient on a valid prescription. Second, pharmacies are expected to use bulk ingredients from FDA-registered suppliers with a certificate of analysis, and sterile preparations are expected to meet USP chapter 797 standards, but oversight of 503A pharmacies rests mainly with state boards and varies in rigor.
The ipamorelin and CJC-1295 combinations often marketed alongside sermorelin were not among the peptides removed from Category 2 in 2026, and neither can lawfully be compounded. Products combining sermorelin with those peptides, or sold as research chemicals, fall outside the legal pathway entirely. For patients and prescribers alike, the practical question for any product is not whether sermorelin is legal in general, but who made this specific preparation, from what, and under which standards.
Compounded sermorelin is most often dispensed as a freeze-dried powder to be mixed with bacteriostatic or sterile water, or as a premixed solution, for subcutaneous injection. Some pharmacies also offer sublingual troches, oral tablets, capsules or nasal sprays, usually marketed as needle-free alternatives.
The pharmacokinetic data that exist come from the approved injectable product. According to its labeling, even subcutaneous injection delivered only about 6% of the dose into the bloodstream compared with intravenous injection, and peak levels were reached within about 5 to 20 minutes. Peptides taken by mouth are largely broken down in the stomach and intestine, and absorption through the lining of the mouth or nose is limited for molecules of this size without special absorption enhancers.
There is no published controlled evidence that oral, sublingual or topical sermorelin raises growth hormone or IGF-1 meaningfully. Intranasal delivery of GHRH analogs has been explored in research settings, but the doses needed are much larger and the results less consistent than with injection. A product that claims equivalent results without an injection should be able to point to data measuring hormone levels after that specific route; most cannot.
Concentration and dosing also vary between pharmacies, which makes comparing protocols difficult. Some pharmacies label in milligrams and others in international units or syringe units, and multi-dose vials require the patient to draw an exact volume. The FDA has documented hospitalizations from dosing errors with compounded injectables when patients confused units, milliliters and milligrams. Clear written instructions stating the dose in milligrams, milliliters and syringe units are a simple safeguard.
Growth hormone is not released at a constant rate. It arrives in bursts across a roughly 24-hour rhythm, with the largest pulses during early deep sleep, and the peaks and troughs appear to be part of how tissues are designed to receive the signal. Two opposing hypothalamic messages govern this: GHRH tells the pituitary to release, and somatostatin tells it to hold. The interplay between them produces the pulses. Blood sugar matters too, because elevated glucose and insulin blunt release, which is the physiological reason sermorelin is typically dosed at night on an empty stomach.
This is where the argument for secretagogues is made. Injected growth hormone produces steady, non-pulsatile levels and suppresses the body's own GHRH output through negative feedback, and endocrinologists generally accept that continuous exposure is more likely to produce the fluid retention, joint pain and insulin resistance seen in growth hormone trials. A GHRH analog works within the existing system and leaves the somatostatin brake intact, so the pituitary retains a ceiling on how much it will release. The reasoning is coherent. What is missing is the step that would make it more than reasoning: trials comparing the two approaches on outcomes that matter, over years, in adults.
Sermorelin is among the shortest-acting peptides used in medicine. The original Geref labeling reported a half-life of about 11 to 12 minutes after either intravenous or subcutaneous administration, reflecting rapid breakdown by enzymes in the blood and tissues. Native GHRH is cleaved within minutes by an enzyme called dipeptidyl peptidase-4, the same enzyme that inactivates natural GLP-1, and sermorelin shares that vulnerability.
The growth hormone response follows the drug's brief presence. After an injection, growth hormone levels rise within minutes, peak within roughly half an hour to an hour, and return toward baseline over the following hours. The effect is a single induced pulse rather than a sustained elevation, which is the pharmacological basis for the argument that sermorelin mimics natural physiology more closely than injected growth hormone does.
The short duration also has costs. A single nightly dose produces one pulse, while the body normally generates several across a 24-hour period. IGF-1, the downstream marker, rises less than with growth hormone injections, and the response varies considerably between people, depending on age, body fat, sleep, glucose levels and pituitary reserve. Older adults and people with more abdominal fat tend to respond less.
These properties explain why drug developers created longer-acting GHRH analogs. Tesamorelin adds a chemical group that slows breakdown, and CJC-1295 was designed to bind albumin and last for days. Neither approach made sermorelin obsolete as a compounded product, but they show that its short half-life was regarded as a limitation rather than an advantage by the companies developing GHRH-based drugs.
Sleep is one of the most common reasons people cite for trying sermorelin, and there is a genuine biological connection. The largest growth hormone pulse of the day normally occurs shortly after sleep onset, during slow-wave sleep, the deepest stage. GHRH appears to do more than coincide with that sleep: in studies in young adults, GHRH given during the night increased slow-wave sleep, suggesting it plays a role in regulating deep sleep itself.
Both deep sleep and nighttime growth hormone decline with age, and researchers have explored whether GHRH could restore them. Results in older adults have been mixed. Some small studies found modest changes in sleep architecture, while others found little effect, and the responses in older people were generally weaker than in the young.
Reports of improved sleep on sermorelin come largely from patient experience and clinic observation rather than controlled trials. Sleep is highly sensitive to expectation, routine and other changes people make when starting a new treatment, so uncontrolled reports are difficult to interpret. That does not mean the effect is imaginary, only that its size and consistency have not been measured.
The relationship also works in the other direction. Poor sleep, sleep apnea, alcohol near bedtime and late eating all suppress nighttime growth hormone release. For many people, addressing those factors directly may influence growth hormone as much as any peptide, and untreated sleep apnea in particular is worth identifying before attributing fatigue or poor recovery to low growth hormone.
The adult research on sermorelin is thin, and being clear about that is more useful than working around it. What exists is largely a set of small studies, many conducted in the 1990s, whose endpoints were hormone levels and short-term body composition rather than long-term clinical outcomes. There is no large randomized trial demonstrating that sermorelin improves bone density, cardiovascular risk, physical function or quality of life in adults over a period of years, and there is no long-term safety dataset of the kind that accompanies an actively marketed drug.
This is worth setting against recombinant growth hormone, which has been studied in adults with diagnosed deficiency for decades and has consistent data on body composition, exercise capacity, bone mineral density, lipids, inflammatory markers and self-reported quality of life, summarized in Endocrine Society clinical practice guidance. Those findings belong to a different drug used in a different population. When they appear in material promoting sermorelin to adults without diagnosed deficiency, the substitution is doing the persuasive work, and recognizing it is the single most useful thing a reader can take from this page.
The idea of using GHRH or sermorelin to counter age-related decline was tested in a series of small studies in the 1990s. Healthy older men and women received nightly or twice-daily injections for periods ranging from two weeks to several months. The consistent finding was hormonal: growth hormone and IGF-1 rose, in some studies toward levels typical of young adults, showing that the aging pituitary can still respond to GHRH.
Effects on body composition and function were less consistent. Some studies reported modest gains in lean body mass or skin thickness, particularly in men, while others found no change, and effects in women were often smaller. Measures of strength, physical performance and quality of life showed little reliable improvement. The studies were small, often with fewer than 30 participants, and short, so they could detect only large effects.
A larger and more rigorous trial used tesamorelin rather than sermorelin. Published in 2012 in the Archives of Neurology, it randomized 152 adults aged 55 to 87, including people with mild cognitive impairment and cognitively healthy older adults, to tesamorelin or placebo for 20 weeks. Tesamorelin raised IGF-1 and produced a modest improvement in executive function compared with placebo, alongside reductions in body fat. It remains one of the best-designed trials of GHRH stimulation in aging, and its results are cautiously encouraging rather than definitive.
Taken together, the aging research shows that GHRH analogs can raise growth hormone in older adults, that body composition effects are modest and inconsistent, and that functional benefits remain unproven. No trial has examined whether sermorelin reduces frailty, fractures, cardiovascular events or mortality, which are the outcomes that would justify long-term use in healthy aging.
Growth hormone and IGF-1 have receptors in the brain, and both influence the survival and connections of nerve cells in laboratory studies. Lower IGF-1 in older adults has been associated in some observational studies with poorer cognitive performance, which led researchers to ask whether restoring the growth hormone axis could protect cognition.
The 2012 tesamorelin trial described above was designed to test that question. Among its 152 participants, 20 weeks of daily tesamorelin improved a composite measure of executive function, the set of skills involved in planning, attention and mental flexibility, compared with placebo, in both the mild cognitive impairment and healthy groups. Verbal memory showed a trend toward improvement that did not reach statistical significance. A follow-up imaging study from the same group reported increases in the brain chemical GABA after treatment.
These findings have not led to an approved use. The trial was relatively short, the improvements were modest, and larger confirmatory trials have not established benefit for dementia prevention or treatment. The results apply to tesamorelin at the doses studied, not to compounded sermorelin, although the mechanism is similar.
For anyone considering sermorelin for cognitive reasons, the honest summary is that GHRH stimulation has shown a small, promising signal in one well-designed trial of a related drug, and that nothing yet shows it prevents cognitive decline. Established measures for brain health, including treating high blood pressure, staying physically active, protecting hearing and managing diabetes, have far stronger evidence.
Adult growth hormone deficiency is a defined clinical entity, generally arising from pituitary disease, surgery, radiation or head trauma, and marked by increased abdominal fat, reduced muscle mass, low bone density and measurable effects on quality of life and cardiovascular risk. Because those features are nonspecific and overlap with ordinary aging and with several unrelated conditions, diagnosis cannot rest on symptoms or on a single hormone measurement.
Formal diagnosis requires stimulation testing: provoking the pituitary and measuring whether it responds. The insulin tolerance test is the historical reference standard, with GHRH plus arginine endorsed by consensus guidelines as the main alternative where the insulin test is contraindicated, reported with sensitivity around 95% and specificity around 91%. IGF-1 has a role as a screening measure because it is stable through the day, but it falls naturally with age and is also lowered by malnutrition, liver disease, untreated hypothyroidism and poorly controlled diabetes. A low IGF-1 raises a question; it does not answer one.
Growth hormone deficiency can originate at two levels. In pituitary deficiency, the growth hormone-producing cells themselves are damaged or lost, usually by a tumor, surgery, radiation, bleeding or injury. In hypothalamic deficiency, the pituitary is intact but receives too little GHRH, or too much somatostatin, so it is under-stimulated. The distinction determines whether a GHRH analog can work at all.
Sermorelin can only amplify what the pituitary is able to produce. In hypothalamic deficiency, supplying the missing stimulus can restore a meaningful response, which was the rationale for its pediatric approval. In pituitary deficiency, there may be few cells left to stimulate, and the response is usually small or absent. This is why growth hormone replacement, rather than GHRH analogs, is the standard treatment for most adults with diagnosed deficiency, since adult cases most often result from pituitary disease or its treatment.
The same principle applies to the gradual decline in growth hormone that comes with aging, which is thought to reflect mainly reduced hypothalamic stimulation and increased somatostatin tone rather than loss of pituitary cells. That is why the aging pituitary still responds to GHRH, as the 1990s studies showed, and why sermorelin is marketed to older adults. Whether restoring the signal is beneficial is a separate question from whether it is possible.
Historically, sermorelin's diagnostic use exploited this distinction: a normal growth hormone response to GHRH suggested the pituitary was capable, pointing toward a hypothalamic problem. That same logic means a person with a damaged pituitary should not expect benefit from sermorelin, and anyone with a history of pituitary tumor, surgery or radiation needs specialist endocrine evaluation rather than a secretagogue.
Because no approved adult product exists, there is no FDA-approved adult dose of sermorelin. The approved pediatric product used a weight-based dose given subcutaneously once daily at bedtime, and the diagnostic product used a single weight-based intravenous injection. Adult protocols used in compounding practice are derived from clinical experience and small studies rather than from dose-finding trials.
As a result, doses, schedules and treatment lengths vary between prescribers. Common features include nightly subcutaneous injection, often with instructions to avoid eating for a period beforehand because high glucose and insulin blunt growth hormone release, and periodic IGF-1 measurement to confirm a response and avoid overshooting the normal range for age. Some protocols use cycles with breaks, on the theory that this prevents the pituitary from becoming less responsive, but that practice has not been tested in controlled trials.
IGF-1 is the most practical guide to dose because it reflects overall growth hormone activity. A reasonable principle, consistent with growth hormone replacement guidelines, is to keep IGF-1 within the normal range for age rather than pushing it to the upper limit or beyond. Higher IGF-1 offers no demonstrated benefit and increases the likelihood of fluid retention, joint pain, insulin resistance and the theoretical long-term risks discussed elsewhere in this guide.
Anyone comparing protocols should keep in mind that differences in reported results between clinics may reflect differences in patient selection, dose, formulation quality and expectation as much as any real difference in effect. Without trials comparing regimens, claims that one protocol is superior to another are opinion rather than evidence.
Reported effects are mostly local and mild: redness, swelling or discomfort at the injection site, along with flushing, headache, dizziness, nausea and a transient warm sensation. Contraindications include known hypersensitivity, pregnancy and breastfeeding, where data are inadequate, and active malignancy, which is a standard exclusion across growth hormone secretagogues because IGF-1 promotes cell growth and inhibits programmed cell death. Untreated hypothyroidism should be corrected first, since it blunts the pituitary's response and makes the treatment unlikely to do anything. Glucocorticoids suppress growth hormone secretion and work against it for the same reason.
The more important point is what is absent. Because there is no long-term controlled dataset, uncommon or delayed effects may simply never have been captured, and the theoretical concerns that follow from raising growth hormone and IGF-1, including reduced insulin sensitivity, fluid retention, joint symptoms and carpal tunnel-type complaints, have not been quantified for this drug in this population. Absence of reported harm in a small, short literature is not the same as evidence of safety. Monitoring IGF-1, thyroid function and glucose during treatment is the practical response to that uncertainty.
Monitoring during sermorelin treatment usually centers on four measurements. IGF-1 shows whether the treatment is raising growth hormone activity and by how much. Fasting glucose or HbA1c checks for the reduced insulin sensitivity that growth hormone can cause. Thyroid function matters because hypothyroidism both blunts the response and, in the pediatric program, developed during treatment in 6.5% of children. Blood pressure and weight help identify fluid retention.
IGF-1 results need careful interpretation. Reference ranges are adjusted for age and sex, and different laboratories use different assays, so results from different labs are not always comparable. A value within the normal range for a person's age is generally the target. A rise from low-normal to mid-normal indicates a biological response but not, by itself, a health benefit.
Timing matters too. IGF-1 changes over weeks rather than days, so measurements are typically repeated after one to three months of treatment. Symptoms such as persistent swelling of the hands or feet, joint pain, numbness or tingling in the fingers, or rising glucose suggest the growth hormone effect may be excessive, and are reasons to reassess the dose.
What monitoring cannot show is whether treatment is preventing disease or extending healthy life, because those outcomes have not been measured for sermorelin. Lab results confirm that the drug is doing something in the body; they do not confirm that it is doing something useful. Keeping that distinction in mind helps prevent a normal-looking IGF-1 from being mistaken for proof of benefit.
The cancer question around sermorelin comes from biology rather than from observed harm. IGF-1 promotes cell growth and division and helps cells avoid programmed cell death, properties that tumors can exploit. Large observational studies have linked higher circulating IGF-1 to modestly higher risks of several cancers, including breast, prostate and colorectal cancer, and people with Laron syndrome, who cannot respond to growth hormone and have very low IGF-1, rarely develop cancer.
The GHRH receptor itself has also drawn attention. It has been found on a range of human tumor cells, and research groups, notably the one led by Andrew Schally, have developed GHRH receptor antagonists that slowed the growth of several cancer types in laboratory and animal studies. That work suggests GHRH signaling can influence some tumors directly, independent of growth hormone, although it has not produced an approved cancer drug.
None of this demonstrates that sermorelin causes cancer. The studies linking IGF-1 to cancer involve natural variation over decades, and the pediatric sermorelin program was not designed or large enough to detect such an effect. Growth hormone replacement in adults with genuine deficiency, keeping IGF-1 in the normal range, has not been clearly linked to increased cancer risk in long-term registries.
The reasonable conclusion is precautionary. Active cancer is a contraindication, a history of cancer calls for individual specialist advice, age-appropriate screening should be current, and IGF-1 should be kept within the normal range for age. These are the same principles applied to growth hormone therapy and to tesamorelin, whose label explicitly lists active malignancy as a contraindication.
Sermorelin is usually discussed alongside several other peptides, and their differences are substantive rather than cosmetic. Tesamorelin is a stabilized analog of the full GHRH(1-44) sequence that received FDA approval in 2010 for reducing excess visceral fat in people with HIV-associated lipodystrophy, supported by randomized trials; it is an approved drug with an approved indication. Macimorelin works through the ghrelin receptor and is approved for diagnosing adult growth hormone deficiency. Ipamorelin and CJC-1295 are frequently marketed as alternatives but were placed in the FDA's Category 2 for potential safety risks and cannot lawfully be compounded.
Two practical consequences follow. First, similarity of mechanism says nothing about regulatory standing or evidence: these compounds occupy very different positions despite acting on the same axis. Second, a source willing to supply peptides that cannot lawfully be compounded is telling you something about how it operates. Material sold under a research use only label is not authorized for human use regardless of how it is marketed, and it carries the added risks of unverified identity, purity, sterility and concentration.
Sermorelin is widely marketed, and much of that marketing blends accurate statements with claims that go beyond the evidence. A few patterns recur. The first is describing sermorelin as FDA-approved. It was approved, for pediatric deficiency and for diagnosis, but no approved product has existed since 2008, and it was never approved for adult use.
The second is borrowing results from other drugs. Benefits documented for recombinant growth hormone in adults with diagnosed deficiency, or for tesamorelin in HIV-associated lipodystrophy, are often presented as if they apply to compounded sermorelin in healthy adults. Each was studied in a different population with a different drug. The third is treating surrogate markers as outcomes: a rise in IGF-1 shows the drug is active, not that it improves health.
The fourth pattern is the natural and safe framing. Sermorelin does work through the body's own control system, which is a genuine physiological point, but natural mechanisms do not guarantee safety, and the long-term safety of raising growth hormone in healthy adults has not been established for any secretagogue. The fifth is before-and-after testimonials, which cannot separate the effect of the drug from changes in diet, training, sleep and expectation.
A useful test for any claim is to ask which drug was studied, in whom, for how long, compared with what, and what outcome was measured. Claims that survive those questions, such as the observation that sermorelin raises growth hormone and IGF-1 in people with an intact pituitary, can be taken at face value. Claims that do not survive them, such as reversal of aging, are hypotheses rather than findings.
Several important questions about sermorelin remain open. The most basic is whether it produces meaningful benefits in adults without diagnosed deficiency. The 1990s studies were too small and short to answer that, and no modern trial has been designed to test it. Outcomes such as strength, physical function, fractures, cardiovascular health and quality of life would all need to be measured over at least a year.
The second is long-term safety. The theoretical concerns about glucose, fluid balance and cancer risk have not been quantified for sermorelin in adults, because no large, long study has followed users. The third is dosing: without dose-finding trials, the optimal dose, schedule and target IGF-1 level for any purpose are unknown, and practices that are common in clinics, such as cycling, have not been tested.
The fourth question is about quality. Compounded sermorelin from different pharmacies may vary in potency, purity and stability, and there is little published data comparing products. Independent testing of compounded peptides has repeatedly found discrepancies between labeled and actual content in products from unregulated sources, but systematic testing of licensed pharmacy preparations is limited.
Finally, the regulatory environment for peptides is changing quickly. Although sermorelin's own compounding status is settled for now, the 2026 FDA decisions on other peptides, possible future generic applications referencing Geref, and state-level oversight of compounding may all affect how it is supplied. Until better evidence exists, sermorelin is best understood as a biologically active compound with a plausible mechanism and a thin adult evidence base, and decisions about it are best made with that balance clearly in view.
Compounded sermorelin is generally kept in the refrigerator, both before and after mixing, and should not be frozen once reconstituted. Beyond-use dates for compounded sterile preparations are set by the pharmacy under USP standards and are usually much shorter than the expiration dates on manufactured drugs, often a matter of weeks after the vial is first punctured. The label on the specific vial is the authority, and a vial that looks cloudy or contains particles when it should be clear should not be used.
Daily injections require a steady supply of syringes, alcohol swabs and a sharps container. Used needles should go into an FDA-cleared sharps container or a heavy-duty plastic container as local rules allow, never loose in household trash. Travel is manageable with an insulated case and cold packs, keeping medication in carry-on luggage with its pharmacy label, since checked baggage can be exposed to temperature extremes.
Cost is usually out of pocket. Insurers generally do not cover compounded preparations used outside an approved indication, and the total cost includes not only the medication but the prescriber's fees and periodic laboratory tests such as IGF-1, glucose and thyroid function. Asking for the full expected cost over six to twelve months, including monitoring, gives a more realistic picture than the price of a single vial.
Adherence is the other practical factor. Because sermorelin acts for minutes and its effects depend on continued use, a missed dose simply means a missed pulse; doubling the next dose is not recommended. Many people find a fixed routine at bedtime easiest to maintain. For anyone subject to drug testing in sport, the practical consideration comes first: sermorelin is prohibited at all times by the World Anti-Doping Agency.
Sermorelin is one of several ways to influence the growth hormone axis, and some of the others require no prescription. Exercise is among the most reliable natural stimuli: moderate to vigorous aerobic exercise and resistance training both produce substantial growth hormone pulses, with larger responses to higher-intensity efforts. Regular training also improves body composition directly, which is the outcome most people are seeking.
Sleep is another. Because the largest daily growth hormone pulse occurs in early deep sleep, consistent sleep of adequate length supports natural secretion, while short sleep, alcohol before bed and untreated sleep apnea suppress it. Body composition matters as well: excess abdominal fat is associated with lower growth hormone secretion, and weight loss tends to increase it. Fasting and lower insulin levels also increase growth hormone release, which is why pulses are larger overnight.
Among prescription options, recombinant growth hormone is the established treatment for diagnosed deficiency, with decades of data in that population. Tesamorelin is the approved GHRH analog for HIV-associated lipodystrophy. For people whose main goal is weight or metabolic health, GLP-1-based medications have far larger and better-documented effects on weight, blood sugar and cardiovascular risk than any growth hormone secretagogue, though they work through entirely different mechanisms. Testosterone therapy is a separate treatment for men with confirmed low testosterone and symptoms.
Framing sermorelin within these options helps set expectations. It can raise growth hormone in people with an intact pituitary, but the measurable benefits in healthy adults are uncertain, while exercise, sleep and weight management have well-documented effects on both the growth hormone axis and overall health. For people with genuine deficiency or specific medical conditions, established treatments with stronger evidence are usually the starting point.
This guide draws on FDA compounding policy documents, peer-reviewed endocrinology literature and clinical trial records. It is provided for general education and does not constitute medical advice. Speak with a licensed healthcare provider about any medication or treatment decision.